Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Fig. 1

Enrollment of patients with T2D who were treated with SGLT2i or DPP4i after PAD revascularization. DPP4i dipeptidyl peptidase-4 inhibitors, PAD peripheral artery disease, SGLT2i sodium–glucose cotransporter-2 inhibitors, T2D type 2 diabetes

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us